Dolutegravir is the generic equivalent to ViiV Healthcare’s drug Tivcay.
India-based Aurobindo Pharma entered a licensing agreement with Viiv Healthcare in 2014 that allows the drugmaker to license dolutegravir in 92 countries, pending the drug’s approval from local regulatory agencies.
Aurobindo Pharma will launch the drug in Africa in late 2016 as part of a collaboration with Viiv Healthcare and the Clinton Health Access Initiative[AC2], which seeks to provide HIV treatments to people in developing countries.
More articles on supply chain:
5 reasons insurance claims should include UDIs
Mylan CEO’s mother advocated for EpiPen sales in school as education leader
Sarepta’s drug approval: The rise of consumer input or the fall of drug standards?
